drugset / Trial / NCT03931590

A Human AME Study for Omaveloxolone

NCT03931590

Phase 1 Completed 8 enrolled Biogen
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the pharmacokinetics (PK), mass balance, metabolite profiles, and rates and routes of elimination of \[14C\] omaveloxolone and derived metabolites following administration as a single 150 mg (containing approximately 90 µCi) dose to healthy male subjects.

Timeline

Start
2019-04-11
Primary completion
2019-05-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Omaveloxolone Small molecule 150 mg Oral

Indications

No indication recorded.